394 related articles for article (PubMed ID: 17276554)
1. Changing perspective on immunization against influenza.
Johansson BE; Brett IC
Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
[TBL] [Abstract][Full Text] [Related]
2. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
3. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
5. Influenza viral neuraminidase: the forgotten antigen.
Johansson BE; Cox MM
Expert Rev Vaccines; 2011 Dec; 10(12):1683-95. PubMed ID: 22085172
[TBL] [Abstract][Full Text] [Related]
6. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
[TBL] [Abstract][Full Text] [Related]
7. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Johansson BE; Kilbourne ED
Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
[TBL] [Abstract][Full Text] [Related]
8. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
9. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
10. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Johansson BE
Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
[TBL] [Abstract][Full Text] [Related]
11. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
[TBL] [Abstract][Full Text] [Related]
12. [Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice].
Ma J; Zhang XG; Li KB; Zhang XM; Wang M; Bai T; Yang L; Xu H; Shu YL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):449-51. PubMed ID: 20718353
[TBL] [Abstract][Full Text] [Related]
13. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
[TBL] [Abstract][Full Text] [Related]
16. Purified viral neuraminidase vaccine to control influenza.
Arora DJ
Can Med Assoc J; 1979 Dec; 121(12):1575-9. PubMed ID: 394829
[TBL] [Abstract][Full Text] [Related]
17. Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.
Pan W; Dong Z; Meng W; Zhang W; Li T; Li C; Zhang B; Chen L
Hum Vaccin Immunother; 2012 Feb; 8(2):252-9. PubMed ID: 22426370
[TBL] [Abstract][Full Text] [Related]
18. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
20. H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens.
Li C; Ping J; Jing B; Deng G; Jiang Y; Li Y; Tian G; Yu K; Bu Z; Chen H
Biochem Biophys Res Commun; 2008 Jul; 372(2):293-7. PubMed ID: 18501701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
